EyeGate is developing and commercializing products for treating diseases and disorders of the eye. The Companyâs products are based on two proprietary platform technologies: EyeGateâs first platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (âCMHA-Sâ), a modified form of the natural polymer hyaluronic acid (âHAâ), which is a gel that possesses unique physical and chemical properties including hydration and healing when applied to the ocular surface. The ability of CMHA-S to protect and adhere longer to the ocular surface, and resist degradation makes it well-suited for treating various ocular surface injuries. EGP-437, EyeGateâs second product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGateâs proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in trials for the treatment of uveitis and pain and inflammation following cataract surgery. EyeGate has granted a subsidiary of Valeant Pharmaceuticals an exclusive worldwide license to the product in these indications. Source
No articles found.
Valeritas is a commercial-stage medical technology company focused on improving he...
Valeritas is a commercial-stage medical technol...
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a ...
Fluidigm (NASDAQ:FLDM) is an industry-leading b...
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Otsuka Holdings Co Ltd is a pharmaceutical company. The Company manufactures, sell...
Otsuka Holdings Co Ltd is a pharmaceutical comp...
Genocea is a biopharmaceutical company developing personalized cancer immunotherap...
Genocea is a biopharmaceutical company developi...
Join the National Investor Network and get the latest information with your interests in mind.